Shares of Valeant Pharmaceuticals (NYSE: VRX) plunged nearly 15% when the company finally reported its 1st quarter earnings on June 7 on a reduced 2016 outlook and a laundry list of other issues.

More than 100 million shares traded that day, five times the previous day's volume, as investors rushed for the exit and short sellers danced a jig.